Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dupilumab - Regeneron/Sanofi

Next Previous
Drug Profile

Dupilumab - Regeneron/Sanofi

Alternative Names: Dupilumab-Sanofi/Regeneron; Dupixent; REGN-668; SAR-231893

Latest Information Update: 03 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals; sanofi-aventis
  • Developer Aimmune Therapeutics; Mayo Clinic; Regeneron Pharmaceuticals; Sanofi; Sanofi-Aventis GmbH
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antifungals; Antineoplastics; Antipruritics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 13 receptor antagonists; Interleukin 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bullous pemphigoid; Eosinophilic oesophagitis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Asthma; Atopic dermatitis; Chronic urticaria; Eosinophilic oesophagitis; Prurigo nodularis; Rhinosinusitis
  • Preregistration Chronic obstructive pulmonary disease
  • Phase III Bullous pemphigoid; Pruritus; Wheezing
  • Phase II/III Eosinophilic gastroenteritis
  • Phase II Aspergillosis; Eczema; Milk hypersensitivity; Prostate cancer; Ulcerative colitis; Urticaria
  • No development reported Allergic asthma
  • Discontinued Grass pollen hypersensitivity; Peanut hypersensitivity

Most Recent Events

  • 03 Apr 2024 Launched for Asthma (Adjunctive treatment, In children) in Norway (SC)
  • 03 Apr 2024 Launched for Atopic dermatitis (Adjunctive treatment, In adolescents) in Norway (SC)
  • 03 Apr 2024 Launched for Atopic dermatitis (Adjunctive treatment, In children) in United Kingdom (SC)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top